Lipopolysaccharides (LPS)

Lipopolysaccharides (LPS) are large molecules found in the outer membrane of Gram-negative bacteria. In the medical field, they are known as endotoxins because they elicit strong immune responses in animals. In the context of Russell Clark's 'Health & Wellness' research, LPS is viewed as a major driver of metabolic endotoxemia. When the gut barrier is compromised (often by lectins or a high-sugar diet), LPS leaks into the bloodstream. Once in circulation, LPS binds to Toll-like receptor 4 (TLR4), triggering an inflammatory cascade that directly causes insulin resistance in the liver, muscle, and adipose tissue. This is a critical component of why many people struggle to lose weight; they are in a state of constant 'immune-metabolic' activation. The Clark Protocol emphasizes gut microbiome repair specifically to reduce the population of LPS-producing bacteria and strengthen the gut barrier to prevent their translocation. During the 'phase 1 priming' and 'phase 2 aggressive loss' stages, we focus on foods that do not promote LPS transport. Reducing systemic LPS is essential for restoring 'leptin sensitivity,' as LPS has been shown to block leptin's ability to reach the brain, thereby preventing the 'satiety signal' from being heard.